Martinaud C, Souraud J-B, Cournac J-M, Pons S, Ménard G, de Jaureguiberry J-P, Brisou P
Fédération des laboratoires, HIA Sainte-Anne, BP 20545, 83041 Toulon cedex 9, France.
Rev Med Interne. 2011 May;32(5):e66-8. doi: 10.1016/j.revmed.2010.06.003. Epub 2010 Jul 14.
We report a 49-year-old man suffering from chronic hypereosinophilia whose biological tests revealed a gene rearrangement between FIP1L1 and PDGFRA as well as a T-cell clonality. After 1 year of therapy with imatinib mesylate (100 mg daily), the patient was clinically asymptomatic, the fusion transcript was undetectable using RTQ-PCR and no lymphoproliferative disorders occurred. This unique combination raises the question of the physiopathology of such a grey zone hypereosinophilia and their management.
我们报告了一名患有慢性嗜酸性粒细胞增多症的49岁男性，其生物学检测显示FIP1L1和PDGFRA之间存在基因重排以及T细胞克隆性。在接受甲磺酸伊马替尼治疗（每日100毫克）1年后，患者临床无症状，使用实时定量聚合酶链反应（RTQ-PCR）检测不到融合转录本，且未发生淋巴增殖性疾病。这种独特的组合引发了关于此类灰色地带嗜酸性粒细胞增多症的病理生理学及其管理的问题。
